193 related articles for article (PubMed ID: 21415240)
1. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study.
Oechsle K; Honecker F; Cheng T; Mayer F; Czaykowski P; Winquist E; Wood L; Fenner M; Glaesener S; Hartmann JT; Chi K; Bokemeyer C; Kollmannsberger C
Ann Oncol; 2011 Dec; 22(12):2654-2660. PubMed ID: 21415240
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
3. Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design.
Feldman DR; Patil S; Trinos MJ; Carousso M; Ginsberg MS; Sheinfeld J; Bajorin DF; Bosl GJ; Motzer RJ
Cancer; 2012 Feb; 118(4):981-6. PubMed ID: 21792865
[TBL] [Abstract][Full Text] [Related]
4. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.
Subbiah V; Meric-Bernstam F; Mills GB; Shaw KR; Bailey AM; Rao P; Ward JF; Pagliaro LC
J Hematol Oncol; 2014 Aug; 7():52. PubMed ID: 25085632
[TBL] [Abstract][Full Text] [Related]
5. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
Fenner M; Oing C; Dieing A; Gauler T; Oechsle K; Lorch A; Hentrich M; Kopp HG; Bokemeyer C; Honecker F
J Cancer Res Clin Oncol; 2019 Mar; 145(3):717-723. PubMed ID: 30232558
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors.
Feldman DR; Turkula S; Ginsberg MS; Ishill N; Patil S; Carousso M; Bosl GJ; Motzer RJ
Invest New Drugs; 2010 Aug; 28(4):523-8. PubMed ID: 19547919
[TBL] [Abstract][Full Text] [Related]
7. Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series.
Oing C; Hentrich M; Lorch A; Gläser D; Rumpold H; Ochsenreither S; Richter S; Dieing A; Zschäbitz S; Pereira RR; Bokemeyer C; Seidel C
J Cancer Res Clin Oncol; 2020 Feb; 146(2):449-455. PubMed ID: 31838576
[TBL] [Abstract][Full Text] [Related]
8. An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.
Oechsle K; Honecker F; Kollmannsberger C; Rick O; Grünwald V; Mayer F; Hartmann JT; Bokemeyer C
Anticancer Drugs; 2007 Mar; 18(3):273-6. PubMed ID: 17264758
[TBL] [Abstract][Full Text] [Related]
9. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
Kollmannsberger C; Rick O; Derigs HG; Schleucher N; Schöffski P; Beyer J; Schoch R; Sayer HG; Gerl A; Kuczyk M; Spott C; Kanz L; Bokemeyer C
J Clin Oncol; 2002 Apr; 20(8):2031-7. PubMed ID: 11956262
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.
Kollmannsberger C; Rick O; Klaproth H; Kubin T; Sayer HG; Hentrich M; Welslau M; Mayer F; Kuczyk M; Spott C; Kanz L; Bokemeyer C
Br J Cancer; 2002 Sep; 87(7):729-32. PubMed ID: 12232755
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors.
Oechsle K; Kollmannsberger C; Honecker F; Mayer F; Waller CF; Hartmann JT; Boehlke I; Bokemeyer C;
Eur Urol; 2011 Oct; 60(4):850-5. PubMed ID: 21704446
[TBL] [Abstract][Full Text] [Related]
12. Brief report: phase II multicenter study of temozolomide in patients with cisplatin-resistant germ cell tumors.
Maroto P; Huddart R; Garcia del Muro X; Horwich A; Paz Ares L; Aparicio J; Germa-Lluch JR
Oncology; 2011; 80(3-4):219-22. PubMed ID: 21734411
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.
Adra N; Einhorn LH; Althouse SK; Ammakkanavar NR; Musapatika D; Albany C; Vaughn D; Hanna NH
Ann Oncol; 2018 Jan; 29(1):209-214. PubMed ID: 29045540
[TBL] [Abstract][Full Text] [Related]
14. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.
Bellmunt J; González-Larriba JL; Prior C; Maroto P; Carles J; Castellano D; Mellado B; Gallardo E; Perez-Gracia JL; Aguilar G; Villanueva X; Albanell J; Calvo A
Ann Oncol; 2011 Dec; 22(12):2646-2653. PubMed ID: 21427062
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of everolimus in refractory testicular germ cell tumors.
Mego M; Svetlovska D; Miskovska V; Obertova J; Palacka P; Rajec J; Sycova-Mila Z; Chovanec M; Rejlekova K; Zuzák P; Ondrus D; Spanik S; Reckova M; Mardiak J
Urol Oncol; 2016 Mar; 34(3):122.e17-22. PubMed ID: 26612480
[TBL] [Abstract][Full Text] [Related]
17. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer.
Albany C; Fazal Z; Singh R; Bikorimana E; Adra N; Hanna NH; Einhorn LH; Perkins SM; Sandusky GE; Christensen BC; Keer H; Fang F; Nephew KP; Spinella MJ
Cancer Med; 2021 Jan; 10(1):156-163. PubMed ID: 33135391
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial.
Mego M; Svetlovska D; Angelis V D; Kalavska K; Lesko P; Makovník M; Obertova J; Orszaghova Z; Palacka P; Rečková M; Rejlekova K; Z SM; Mardiak J; Chovanec M
Invest New Drugs; 2022 Oct; 40(5):1080-1086. PubMed ID: 35763178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
